Pulmonx (LUNG) Q2 FY26 earnings call

Pulmonx is executing on its strategy to re-accelerate sales growth and drive operating leverage, with Q2 FY26 results showing significant progress in reducing losses and strengthening the balance sheet. The company is rebuilding its U.S. sales force and has secured China registration renewal, positioning for global sales growth later in the year and into next year. Clinical initiatives like the Convert-2 trial continue to advance, aiming for market expansion.